Jonathan Wosen is STAT’s West Coast biotech & life sciences reporter. You can reach Jonathan on Signal at jwosen.27. Facing charges from the Securities and Exchange Commission for misleading claims ...

The stock price of Cassava Sciences (NASDAQ: SAVA) plunged 23% yesterday after a report that the U.S. SEC is investigating the company over allegations of data manipulation for its experimental ...

Shares of clinical-stage biotech Cassava Sciences (NASDAQ: SAVA) soared in 2021 for a couple of reasons. First, the company produced strong results in clinical studies for its potential therapy for ...

Good biotech companies develop and commercialize medicines that are safe and effective. Good medicines tend to be the result of good science. And while defining good science is beyond the scope of ...

Shares of Cassava Sciences (NASDAQ: SAVA) were skyrocketing 29.6% higher as of 10:53 a.m. ET on Monday. The big gain came after executive chairman Rick Barry released an open letter to shareholders, ...

Cassava Sciences, Inc. (NASDAQ:SAVA) saw its stock price surge Wednesday following a major announcement regarding its Alzheimer’s treatment, simufilam. What Happened: At last check, the company is ...

Adam Feuerstein is a senior writer and biotech columnist, reporting on the crossroads of drug development, business, Wall Street, and biotechnology. He is also a co-host of the weekly biotech podcast ...

Cassava Sciences Inc.’s Chief Executive Remi Barbier said on Friday that recent allegations of fraud were “false and misleading” and were a result of investor interests to drive down the price of the ...

The controversy about alleged data manipulation related to simufilam was stirred up again by a leaked report. Cassava's response noted that the report from CUNY didn't make any findings of data ...